quote:

---

Originally posted by sick money:
The other LBTT thread says they are FDA approved

---

Lifeline BioTechnologies, Inc. (LBTI) Recognizes Meaningful Accomplishments In 2003; Company Expectations For 2004 Appear Promising

RENO, Nev.--(BUSINESS WIRE)--Dec. 30, 2003--At Lifeline BioTechnologies Inc.'s (NQB: LBTT - News) year-end annual management meeting, company executives reviewed the accomplishments during the year against the objectives it set out to complete in 2003. Jim Holmes, CEO, announced that this year will stand out in the company's history as a turning point in the development of a number of key elements of the company's strategic plan.

Holmes commented on the following major accomplishments: Although the introduction of First Warning System(TM) into the Chinese market was indeed a milestone, just finding the proper business partner in this distant market presents its own challenges. Even though progress has been slower than originally anticipated due to Chinese government regulations and potential price barriers, patient testing continues, and sales could occur in the coming new year.

NippleScope(TM) received the CE Mark in late 2003, which allows the company to initiate sales efforts in Europe and others markets where the CE is accepted. Lifeline BioTechnologies is planning its initial introduction of the NippleScope(TM) at the annual Cancer Congress in Munich, Germany in March of 2004. Dr. Kefah Mokbel, the company's lead investigator in Europe, will be presenting a lecture on his experience with Lifeline's NippleScope(TM) during this meeting. Initial sales in Europe are expected in first and second quarters of 2004; application for FDA clearance of this scope has been accelerated. Initial domestic (U.S.) sales of the NippleScope(TM) may occur as early as the second quarter of 2004.

Testing of Lifeline's ovarian scope has not moved forward as quickly as anticipated. Management is seeking alternative test sites for this promising, albeit very early stage, medical product.

Lifeline secured the Arthronet exclusive distribution agreement earlier this year. Initial product sales have begun through its national distribution, and are expected to increase in 2004.

The prospects for 2004 are promising with important areas as a priority. The company continues to seek financing and is in preliminary discussions with a major Wall Street firm; other prospective funding sources are also being considered.

The year-end accounting is being wound up and the financial audit is expected to be underway in January.

Dr. William H. Reeves, president and founder of Lifeline BioTechnologies, commented concerning Lifeline's flagship product, the First Warning System(TM) (FWS). "The FWS is a process that is designed to assist in the early detection of breast cancer, and the research group and I feel confident that we are coming closer to a resolution, and an understanding, of the role of the physiologic behavior of those benign breast lesions, which become cancers. Our success will undoubtedly be a breakthrough in medicine and breast cancer detection. Once resolved, the FWS will advance to the final phase clinical trials."

Concluding, the entire management team wishes its friends and shareholders a very safe and happy new year.

Company's Web site: www.lbti.com

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In particular, when used in the preceding discussion, the words "believes," "expects," "intends," "will," "anticipated," or "may," and similar conditional expressions are intended to identify forward-looking statements within the meaning of the act and subject to the safe harbor created by the act. Except for historical information, all of the statements, expectations and assumptions contained in the foregoing are forward-looking statements that involve a number of risks and uncertainties.

Contact:

Lifeline BioTechnologies Inc., Reno Jim Holmes, 775-324-1933 jholmes777@aol.com or Stock Enterprises Investor Relations, 866-242-2405 stockenter@aol.com

Source: Lifeline BioTechnologies Inc.

--------------------------------------------------------------------------------

Post a Trial
View the CCIS Terms and Conditions
Have an idea for improving the CCIS system? Try the CCIS Suggestion Box

--------------------------------------------------------------------------------
Copyright 1995-2004
East Coast: BioSpace
300 Fifth Avenue South
Naples, Florida 34102 U.S.A.
Phone: 239-659-0100
Fax: 239-659-0111

quote:

---

Originally posted by webman:
It has not received FDA approval yet. If you read close it says "we have completed the required documentation for compliance and FDA clearance". In other words, IMO, they have applied for FDA approval but has not been given YET.

---

EXACTLY! There was some vagueness so I pulled out the most recent release.

quote:

---

Originally posted by mjs0987:
I think that I read that they were going to show the equipment at a show in Las Vegas. I think that I also read that it was approved outside the united states. I am in this for 35000 shares. I think it is a very important medical device. It is just an emerging company that has to generate credibiliy and needs strong leadership. It is at .025the last I saw. I think it is a long jourmey but rewarding at the end.

---

According to the CEO Jim Holmes they have approval on their Mammoscope f/k/a Nipplescope (name changed about 3 weeks ago). People argued for 2 days on the last PR on RB's website over the vague PR on FDA approval and/or clearance. A poster on RB called Biotechstocker talked with CEO Jim Holmes over the phone and he told him it's a DONE DEAL on FDA approval on the Mammoscope. (I think what LBTT is waiting for is the paperwork to go through to make it official). I know the PR should of stated FDA approval and instead the PR called it FDA clearance and had everyone confused - so that's why people were debating what this meant. The phone conversation with CEO Jim Holmes and Biotechstocker cleared this up. A lot of people on RB were speculating reasons why the PR was so vague. They seemed to lean toward the company letting the shareholders know what was going on with the Mammoscope and the possibility of the company buying back shares at a lower price before the April 1st deadline (Naked Shorting - hopefully gone). In April at the Vegas show THEY WILL be selling their Mammoscope the CEO said. Also the CEO told Biotechstocker that sometime in April the auditing of the company will be completed and they will be on the OCTBB by the middle of the year. This was great news because this wasn't in the PR. So with 5 shows coming up in March - sales of their Arthronet blades and Inion's bioabsorbable screws coming in in April - financing from a major NASDAQ comapny - being listed on OCTBB by the middle of the year - and this list doesn't end. Do some DD and see for yourself! Now LBTT can sell their Mammoscope here and abroad. I'd say LBTT is well on there way to helping save a lot of women's lives from breast cancer. Esp. with their First Warning System (FWS) and their Mammoscope which are years ahead of the Mammogram (which you can only find in clinics and hospitals) in detecting breast cancer. This equipment that LBTT has will detect cancer before it even starts to spread. The FWS and Mammogram are so small that they (hopefully) will be in every doctors office around the world some day. Tell me women won't DEMAND this over the Mammogram (crunchings). They also will be coming out with their Ovascope for Ovarian cancer in the near future. Who knows what other scopes will be next with this company. Maybe it could be a Rectoscope? All I know imho that this is a great company to have shares in. It's not like they have one product - they have about 5 or 6 going for them. This company has 898 mil. o/s and on the RB message board alone over 35% are held by longs. The majority feel that in a year of so that the price per share will be well over a dollar. I've read on RB that Lebed (19 yr. old whiz kid) has picked LBTT as the best Pink Sheet stock out there. GLTA

Interesting, I'm already in. Thanks for clearing up some issues. I don't visit the RB myself, no time. I am also a sceptic so its hard for me to trust someone elses phone calls. I really like what I see from them also.

Is the major funding from a nasdaq company still unknown?

Buying back shares is news to me. Hope you are right. Over a buck, why not, look at MDDM.

I think their product line will do well and I hoping to gather reaction from the conferences to gauge whether to sell or hold.

Believe me I no paid basher. I've been in the stock market for about 4 or 5 yrs. now. Last summer I sold all my stocks (about 37 biotech ones) and bought into the penny stocks. I had about 8 or so and now have 2 left. I personally have 2,688,082 shares of LBTT (listed under the Millionaire's Club on the RB message board under Boutman group) for a total (with group) of over 4.5 mil. shares with my 2 brothers - friends and co-workers) and 50 mil. shares of CMKM (my lottery tickets). I use to have 1.75 mil. shares of IBZT and sold them to buy more of LBTT. Every night I'm on the RB message boards reading all the info I can find. I very rarely post there (I think 3 or 4 times & 3 were updates on the Mil. list) I've been a member of Allstocks since this past summer and rarely post anything now. I'm not a member anywhere else either. I was just stating some facts mostly from PR's and the phone conversation. Since I have so many shares I keep myself well informed on this company. I know the phone is another matter but if you've read the RB message board as long as I have you'd see that Biotechstocker is very well respected over there. I've posted on CMKM here on some DD but that was probably 6 months ago. You can't be a basher if you hardly ever post. Everything I posted was taken from PR's and that one phone conversation. GLTY

Bruce

I never said you were a paid basher, I said pumper. There is a big difference. What is your entry position, mine is just above .02 per share. Sounds like you're betting the farm on LBTT, be careful. Like I said, they have way too many O/S and either need to reverse spilt this issue or start buying back aggressively. If this is so great, are the officers of the company buying shares?

I just read my message and I meant to say pumper not basher. Sorry. I also forgot to answer one of your questions. A few months ago the CEO of LBTT had mentioned in one of their PR's that there would be no R/S.

Keithsan, the company is still in negotiation with a NASDAQ co. as stated by the CEO. He didn't rule out that more shares would be issued - but only to the co. with the financing.

Bruce

Well, if that is the case, what about a buy-back effort? You're 2.6M shares may be subject to even more dilution. I too have the CMKM lottery ticket, but all shares are now free. I wish you the best, but with LBTT approaching 1B shares....who knows...

Made some good $$ on QBID.

Find the next TASR...could be MDDM.

The buy back was only speculation by the longs on RB. They thought this because of the vague PR that came out the other day. I hope they are buying back shares here and there. I first started buying LBTT when it was only .0019 ) a share. One week after I bought most of my shares it did 100% gain and the next day the same. When my brothers - friends & co-workers seen I was making money - they all wanted LBTT. And the reason they all wanted in is because they all think I swallowed a hor$e$hoe when I was a kid. I do have a 5 leaf clover I found a few years ago and put it in a small picture frame between 2 pieces of glass and it turned to gold when it dried out. Yes I am that lucky just like my life has mostly been. I'm always winning something. My average pps right now is .0046. I just got my tax money back and have another $1,400 to buy more. I would like to see the price drop a little. It probably will (unless another PR comes out) because the April 1st deadline is still weeks away and plenty of time for the MM's to drag it down (along with all the other pink sheet stocks). There day will come and I hope the deadline sticks this time on April 1st. Now we need to find out who the big NASDAQ co. who'll finance LBTT will be.

I'm in at .025 a share myself. Just recently involved myself with the Pennys and jumped on this one a little bit back.

From what I read on the last PR and the 2 different emails from CEO Jim Holmes (that was posted on RB) they already have FDA approval or clearance as its read in the PR. He mentions they are approved in the 2 emails and will be selling the Mammoscope (new name as stated in a PR about 3 weeks ago) at the Las Vega$ convention. I think they're waiting on the ink to dry before changing clearance to approval officially. He mentioned they will be selling the scope in LV and that means in order to sell it they have to have approval. No? Otherwise who would buy it if it wasn't approved. There is somethng that the CEO is keeping from the shareholders on this clearification through that last PR though. What it is I don't know. I guest we will find out soon enough.

In theory, a R/S is a good thing because it gets the issue closer to the NASDAQ trading rules as the price should go North from here, unless it is done solely to line the pockets of the company officers. I happen to own shares of this company and I am thinking a R/S would be a good thing for this company if it is done in the right context. Sorry about your 4M shares being devastated, but I have been there myself only to have the company go right back to what I originally paid for it in the first place, it really sucks!

The CEO said there would be no more r/s. Well that's what he said. I personally don't think there will be one. I know we have a float of 898 mil. shares. Look at SIRI (Sirius Satellite Radio) they have a float of 944 mil. shares and this past Friday they closed out at $2.94 a share. What they have to offer is satellite radio and what LBTT has to offer is early detection of breast cancer. Sales will bring the price of this stock up. I hope we get great news from the 5 conventions this month.

Lifeline BioTechnologies Clarifies an
Earlier News Release as Management Prepares to Attend Industry Trade Shows
Monday March 1, 9:01 am ET

RENO, Nev.--(BUSINESS WIRE)--March 1, 2004--Jim Holmes, CEO of Lifeline BioTechnologies, (OTC:LBTT - News) today clarified the press release of February 26, 2004, in that some shareholders found it somewhat confusing.
Dr. William Reeves, Lifeline's president and founder, stated that clarification of terms on last week's news release about the MammaScope(TM) regulatory clearances was needed. Reeves said, "Lifeline will begin to sell the MammaScope(TM) in the United States as well as Europe. European sales can commence because the Company has obtained CE certification, which permits sales in all Common Market countries. European sales will formally begin at the 4th Annual European Breast Cancer Congress in Hamburg, Germany, March 16-20. Following the Hamburg meeting, Lifeline will attend the American Society of Breast Surgeons' 5th Annual Meeting to be held in Las Vegas March 31 through April 4, where it will introduce the MammaScope(TM) into the U.S. market. The company will market the MammaScope(TM) under a recently acquired 510(k) clearance."

Commenting on further development of Lifeline's First Warning Breast Monitoring System(TM), Reeves noted that development continues in its efforts to separate "false positive" benign breast lesions that will develop into breast cancers at some later date in the patient's life from "false positive" benign lesions which are truly harmless and present no danger to the patient. Lifeline's scientists have focused this upgrade of the interpretive system on recent discoveries. A number of independent consultants have been retained, and are assisting Lifeline in the interpretive system upgrade, in particular, the noted chronobiologist, Dr. Max Moser of the University of Graz, in Austria. Dr. Moser has invited Dr. Reeves and Mr. Holmes to Graz, following the Hamburg Conference, to speak to several groups of Austrian surgeons and oncologists about the First Warning Breast Monitoring System(TM). Reeves suggested that these meetings could lead to additional testing of the First Warning Breast Monitoring System(TM) in Austria as part of the final phase clinical trials necessary before the final data submission to the FDA for marketing clearance.

Holmes noted Lifeline will attend three medical industry trade shows in March in the U.S. where the Company will feature the Arthronet Shaver Blade and the Inion Bioabsorable Screw. This promotion will assist in the introduction of these products to the U.S. market and is expected to increase sales. Holmes went on to say, "These products are being made available through more of Lifeline's distributors, nationwide."

Reeves and Holmes reported that the OvaScope(TM) is being tested on a very preliminary basis in an attempt to confirm laboratory expectations of the device. If the testing provides the data expected, testing will be expanded. Holmes noted that if testing is successful, production models will be produced. Reeves said, "The OvaScope(TM) has several predicate devices on the U.S. market, currently; thus a long regulatory process to market clearance would not be anticipated."

Lifeline's website: www.lbti.com

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In particular, when used in the preceding discussion, the words "believe," "expects," "projects," "forecasts," "intends," "will," "anticipated," "could," or "may," and similar conditional expressions are intended to identify forward-looking statements within the meaning of the act. Except for historical information, all of the statements, expectations and assumptions contained in the foregoing are forward-looking statements that involve a number of risks and uncertainties.

--------------------------------------------------------------------------------
Contact:
Lifeline BioTechnologies, Inc.
Jim Holmes, 775-324-1933
jholmes@lbti.com
or
Stock Enterprises
Investor Relations:
Jim Stock, 866-242-2405
stockenter@aol.com